Table 5.
Combinations of PARP inhibitors with immunotherapy agents for the treatment of recurrent ovarian cancer
| Trial name/identification | Phase | Treatment(s) | Disease setting | Sample size | Follow-up (median months) | Objective response rate (%) |
Progression -free survival (median months) |
Overall survival (median months) |
| MEDIOLA (Drew et al. 2018)49 | I/II | Olaparib+ durvalumab |
Recurrent platinum-sensitive ovarian cancer | 32 | Not reported | 72% | 11.1 | Not reported |
| MEDIOLA (Drew et al. 2020)61 | II | Olaparib+ durvalumab olaparib+ durvalumab+ bevacizumab |
Recurrent platinum-sensitive non-germline BRCA-mutated ovarian cancer | 32 31 |
Not reported Not reported | 31.3% 77.4% |
5.5 14.7 |
Not reported Not reported |
| TOPACIO (Konstantinopoulos et al. 2019)50 | I/II | Niraparib+ pembrolizumab |
Platinum-resistant recurrent epithelial ovarian cancer | 60 | 12.4 | 18% | 3.4 | Not reported |
| Lampert et al. 2020 51 | II | Olaparib+ durvalumab |
Platinum-resistant recurrent ovarian cancer | 35 | Not reported | 14% | 3.9 | Not reported |
| Gaillard et al. 2020 52 | I/II | Tremelimumab vs tremelimumab +olaparib |
Platinum-resistant recurrent ovarian cancer | 24 | Not reported | 1 partial response and 3 disease stabilizations with tremelimumab +olaparib; 6 disease stabilizations with tremelimumab |
2 >6 month progression-free survival with tremelimumab +olaparib |
Not reported |
BRCA, BReast CAncer gene; PARP, poly-ADP ribose polymerase.